AC102
Idiopathic Sudden Sensorineural Hearing Loss (ISSNHL)
Key Facts
About AudioCure Pharma
AudioCure Pharma is a private, clinical-stage biotech based in Berlin, Germany, founded in 2015 (operational since 2012) to develop first-in-class pharmacotherapies for hearing disorders. The company's core asset is AC102, a novel small molecule currently in Phase II for idiopathic sudden sensorineural hearing loss (ISSNHL), with a completed Phase I trial in 2021. Targeting a massive market with no approved drugs, AudioCure's strategy is to move beyond symptomatic treatment to directly protect and restore inner ear cells and their connections. The company is led by a seasoned CEO and its founder, a clinician-scientist, and is backed by strategic investors and academic partners like Charité University.
View full company profile